Processa Pharmaceuticals Stock Today
| PCSA Stock | USD 0.21 0.01 4.55% |
PerformanceWeak
| Odds Of DistressVery High
|
Processa Pharmaceuticals is trading at 0.21 as of the 19th of July 2025, a 4.55 percent decrease since the beginning of the trading day. The stock's open price was 0.22. Processa Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of June 2025 and ending today, the 19th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of October 2017 | Category Healthcare | Classification Health Care |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. The company has 26.19 M outstanding shares of which 859.99 K shares are at this time shorted by private and institutional investors with about 0.1 trading days to cover. More on Processa Pharmaceuticals
Moving together with Processa Stock
Moving against Processa Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Processa Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsProcessa Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Processa Pharmaceuticals' financial leverage. It provides some insight into what part of Processa Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Processa Pharmaceuticals (PCSA) is traded on NASDAQ Exchange in USA. It is located in 7380 Coca Cola Drive, Hanover, MD, United States, 21076 and employs 10 people. Processa Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.58 M. Processa Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 26.19 M outstanding shares of which 859.99 K shares are at this time shorted by private and institutional investors with about 0.1 trading days to cover.
Processa Pharmaceuticals currently holds about 12.06 M in cash with (11.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Processa Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationProcessa Pharmaceuticals owns a total of 26.19 Million outstanding shares. Processa Pharmaceuticals holds 11.6 pct. of its outstanding shares held by insiders and 9.05 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Processa Ownership Details
Processa Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Absolute Investment Management Llc | 2024-12-31 | 0.0 | |
| Hrt Financial Llc | 2025-03-31 | 0.0 | |
| Armistice Capital, Llc | 2025-03-31 | 56 K | |
| Virtu Financial Llc | 2025-03-31 | 43.2 K | |
| Geode Capital Management, Llc | 2025-03-31 | 34.4 K | |
| Vanguard Group Inc | 2025-03-31 | 24.4 K | |
| Miracle Mile Advisors, Inc. | 2025-03-31 | 10 K | |
| Tower Research Capital Llc | 2025-03-31 | 2.5 K | |
| Wells Fargo & Co | 2025-03-31 | 154 | |
| Ubs Group Ag | 2025-03-31 | 56.0 | |
| Bank Of America Corp | 2025-03-31 | 37.0 |
Processa Pharmaceuticals Historical Income Statement
Processa Stock Against Markets
Processa Pharmaceuticals Corporate Management
| James Stanker | Chief Officer | Profile | |
| PharmD Bigora | CoFounder Officer | Profile | |
| Russell MBA | Chief Officer | Profile | |
| Steven MD | Senior Research | Profile | |
| Robert Floyd | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.